More Satraplatin Pain For GPC As Other Shoe Drops
This article was originally published in The Pink Sheet Daily
Celgene backs out of overseas deal for failed prostate-cancer chemo.
You may also be interested in...
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
German firm is planning workforce reductions after satraplatin did not show a survival benefit in prostate cancer patients